SARS-CoV-2 NSP12 Protein Is Not an Interferon-β Antagonist
Aixin Li, Kaitao Zhao, Bei Zhang, Rong-Hong Hua, Yujie Fang, Wuhui Jiang, Jing Zhang, Lixia Hui, Yingcheng Zheng, Yan Li, Chengliang Zhu, Pei‐Hui Wang, Ke Peng, Yuchen Xia
Abstract
Previous studies investigated the interaction between SARS-CoV-2 viral proteins and interferon signaling and proposed that several SARS-CoV-2 viral proteins, including NSP12, could suppress IFN-β activation. However, most of these results were generated from IFN-β promoter luciferase reporter assay and have not been validated functionally. In our study, we found that, although NSP12 could suppress IFN-β promoter luciferase activity, it showed no inhibitory effect on IFN-β production or its downstream signaling. Further study revealed that contradictory results could be generated from different experiment systems. On one hand, we demonstrated that SARS-CoV-2 NSP12 could not suppress IFN-β signaling. On the other hand, our study suggests that caution needs to be taken with the interpretation of SARS-CoV-2-related luciferase assays.